Eisai increases the number of participants in Clarity AD study
Stockholm, February 3, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately 200 in the pivotal Phase 3 study, Clarity AD, of drug candidate lecanemab (BAN2401) for the treatment of early Alzheimer’s disease. The decision was taken proactively to ensure a robust dataset and to mitigate the potential impact of patients who temporarily missed doses due to the COVID-19 pandemic. It was based on a collaborative consultation with the FDA and in accordance with FDA and EMA COVID-19 regulatory